Eisai Clinical Trials

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma


Study Overview

eribulin mesilate
Nov 2011 - Nov 2014
Soft Tissue Sarcoma
Progression-free rate (PFR)

  • Males and females (age 20 years and over)

  • Completed

  • Phase 2

  • Japan


CSR Synopsis

Download PDF

Lay Summary

Download PDF
Publication reference citation

Kawai A, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol 2017 02;47(2):137-144. DOI: 10.1093/jjco/hyw175

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Sample CRF
Full CSR